Advertisement LABEC expands IncellDx HPV OncoTect assay throughout Europe - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

LABEC expands IncellDx HPV OncoTect assay throughout Europe

LABEC Pharma and the Labco system have announced the expansion of IncellDx's HPV OncoTect assay throughout the LABEC's entire network in Europe.

Labco has been offering HPV OncoTect, a cervical cancer test, on a limited basis since 2010.

The HPV OncoTect assay quantifies the overexpression of E6/E7 mRNA, the cancer-causing genes of HPV, in each cell and the total proportion of cells that are overexpressing E6/E7 mRNA.

IncellDx CEO Bruce Patterson said Labco is one of the largest laboratories in Europe and represents an important partner in their continued growth in Europe.